Chemotherapy plus sequential hormonal therapy for advanced and recurrent endometrial carcinoma: a phase II study.

Abstract

We evaluated the therapeutic value of sequential cyclical hormonal therapy (megestrol acetate, and tamoxifen citrate) plus single-agent chemotherapy (carboplatin) in the outpatient management of advanced or recurrent endometrial cancer. Carboplatin (300 mg/m2) was administered every 4 weeks for six courses or until disease progression. In addition, patients alternated megestrol acetate (80 mg orally twice daily) with tamoxifen citrate (20 mg orally twice daily) every 3 weeks. Thirteen of 18 (72.2%) patients were considered evaluable. Four patients (30.8%) had a complete response, six (46.2%) had a partial response, one (7.7%) had stable disease, and two patients (15.4%) progressed. Six of seven patients with vaginal disease responded. The median progression-free interval was 14 months for complete responders. Two patients (15.4%) are alive with no evidence of disease at 41 and 59 months. Seven of 13 patients experienced a hematologic toxicity (six grade 2, one grade 3); all resolved within 2 weeks. Dose reduction of carboplatin to 200 mg/m2 was required in one patient. No other toxicities were encountered. The median survival for all patients is 11 months, and is 33 months for complete responders. We conclude that a regimen of carboplatin plus sequential hormonal therapy shows promise in this pilot study for the treatment of advanced or recurrent endometrial cancer.

• Authors: D M Pinelli, J V Fiorica, W S Roberts, M S Hoffman, S V Nicosia, D Cavanagh
• Journal: Gynecologic oncology (Gynecol Oncol) Vol. 60 Issue 3 Pg. 462-7 (Mar 1996) ISSN: 0090-8258 [Print] United States
• PMID: 8774658 (Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article)

Chemical References

• Receptors, Estrogen
• Receptors, Progesterone
• Tamoxifen
• Carboplatin
• Megestrol Acetate

Topics

• Adult
• Aged
• Carboplatin (adverse effects, therapeutic use)
• Carcinoma (drug therapy, metabolism, pathology)
• Disease Progression
• Drug Therapy, Combination
• Endometrial Neoplasms (drug therapy, metabolism, pathology)
• Female
• Humans
• Megestrol Acetate (adverse effects, therapeutic use)
• Middle Aged
• Neoplasm Recurrence, Local
• Receptors, Estrogen (metabolism)
• Receptors, Progesterone (metabolism)
• Survival Analysis
• Tamoxifen (adverse effects, therapeutic use)